Long-Term Real-World Outcomes of Mepolizumab and Benralizumab Among Biologic-Naive Patients With Severe Eosinophilic Asthma: Experience of 3 Years' Therapy

Correction Critical Care Medicine

Real World Effectiveness of Benralizumab in Severe Eosinophilic Asthma (vol 159, pg 496, 2022)

[Anonymous]

CHEST (2023)

Article Allergy

Use of FeNO to predict anti-IL-5 and IL-5R biologics efficacy in a real-world cohort of adults with severe eosinophilic asthma

C. Menigoz et al.

Summary: In this real-world study, adults with severe eosinophilic asthma (SEA) who had a baseline FeNO >= 50 ppb experienced a greater decrease in exacerbations after 12 months of anti-IL-5 or IL-5R biologics.

JOURNAL OF ASTHMA (2023)

Add to Collection

Review Allergy

Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis

David Charles et al.

Summary: This systematic review evaluates the real-world efficacy of recently and nearly licensed biological therapies for severe asthma. The results demonstrate that anti-IL5 biologicals may improve clinical outcomes in patients with severe asthma in a clinic environment with similar effect sizes to randomized controlled trials.

CLINICAL AND EXPERIMENTAL ALLERGY (2022)

Add to Collection

Article Critical Care Medicine

Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study

Andrew Menzies-Gow et al.

Summary: This study evaluated the impact of reducing oral corticosteroids after initiating benralizumab treatment on patients with severe eosinophilic asthma. The study found that with a personalized dosage reduction algorithm, most patients were able to successfully reduce or eliminate the use of oral corticosteroids, and the treatment was safe.

LANCET RESPIRATORY MEDICINE (2022)

Add to Collection

Article Medicine, Research & Experimental

Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab

Andrew Menzies-Gow et al.

Summary: This study demonstrates the potential for disease remission in severe asthma patients treated with benralizumab through a composite remission definition. Results show that precision medicines like benralizumab can improve symptoms and help patients achieve disease remission, indicating a shift towards a treat-to-target approach with clinical remission as the ultimate therapeutic goal in severe asthma.

ADVANCES IN THERAPY (2022)

Add to Collection

Article Allergy

Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarker-high and -low severe asthma

Latifa Khalfaoui et al.

Summary: Airway pathology in severe asthma varies depending on the levels of T2 biomarkers, with similar inflammatory and structural cell activation present in both T2-high and T2-low asthma, but with higher levels of sputum T2-associated cytokines in T2-high patients.

ALLERGY (2022)

Add to Collection

Letter Allergy

Comparative features of eosinophilic and non-eosinophilic asthma

Isabelle Xu et al.

CLINICAL AND EXPERIMENTAL ALLERGY (2022)

Add to Collection

Article Respiratory System

Asthma remission: what is it and how can it be achieved?

Dennis Thomas et al.

Summary: This review discusses the definitions, prevalence, predictors, pathophysiology, treatment possibilities, and research directions of asthma remission. Remission is characterized by high level of disease control and normalized or optimized lung function. Even in symptomatic remission, persistent pathological abnormalities and risk of relapse exist. The prevalence of remission varies between 2% and 52% in adult asthma population. Factors associated with remission include mild asthma, better lung function, better asthma control, younger age, early-onset asthma, shorter duration of asthma, milder bronchial hyperresponsiveness, fewer comorbidities, and smoking cessation or never smoking. Current long-term add-on therapies can achieve some criteria for remission in a subgroup of patients. Further research is required to evaluate remission as a treatment goal.

EUROPEAN RESPIRATORY JOURNAL (2022)

Add to Collection

Article Allergy

Blood eosinophil count and FeNO to predict benralizumab effectiveness in real-life severe asthma patients

Hirofumi Watanabe et al.

Summary: Benralizumab was effective in improving symptoms and reducing exacerbation frequency in patients with severe uncontrolled asthma. The majority of patients showed significant improvements in asthma control measures after 4 weeks of treatment, which continued through 24 weeks. Blood eosinophil count and FeNO levels at baseline can predict the effectiveness of benralizumab treatment.

JOURNAL OF ASTHMA (2022)

Add to Collection

Article Allergy

Increase in FeNO Levels Following IL5/IL5R-Targeting Therapies in Severe Asthma: A Case Series

Genevieve Pelletier et al.

Summary: This study investigates the increase in FeNO levels in a subgroup of severe asthma patients after initiation of anti-IL5/IL5R therapy. The results showed that although FeNO levels increased temporarily, it did not affect clinical outcomes. Further research is needed to understand the underlying mechanisms.

JOURNAL OF ASTHMA AND ALLERGY (2022)

Add to Collection

Article Respiratory System

Life-changing: the experience of super-responders to biologics in severe asthma

Joseph W. Lanario et al.

Summary: This study examined the patient's perspective of being considered a super-responder to biologic treatment for severe asthma. The findings revealed that biologic treatment had profound and heterogeneous effects on the participants' lives, beyond asthma symptoms and exacerbations. These effects included improvements in social and family life, as well as mental health. However, individual variations in response were noted. The study suggests that current research may underestimate the benefits of biologic treatment, as social and family benefits are not reliably measured.

BMC PULMONARY MEDICINE (2022)

Add to Collection

Article Allergy

Discontinuing Omalizumab Treatment in Super-Responder Patients with Allergic Severe Asthma: Can the Baseline Total IgE Level Be Used as a Biological Marker to Decide Discontinuing Omalizumab Treatment?

Bahar Arslan et al.

Summary: This study investigated the clinical effects and persistence of response after discontinuation of omalizumab treatment in severe asthma patients. The results showed that one-third of the patients required retreatment after discontinuation. Additionally, higher baseline total IgE levels may help predict the need for retreatment after discontinuation.

INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY (2022)

Add to Collection

Article Allergy

Analysis of response of severe eosinophilic asthmatic patients to benralizumab

Juan Carlos Miralles-Lopez et al.

Summary: This study describes the super-responders to benralizumab in a series of 79 patients with severe eosinophilic asthma and compares them to non super-responders. The results show that almost two-thirds of the patients were super-responders and 36% had a complete response. Super-responders were associated with older age, higher eosinophils count, nasal polyposis as comorbidity, and less severe disease at baseline.

ALLERGOLOGIA ET IMMUNOPATHOLOGIA (2022)

Add to Collection

Article Allergy

Severe Asthma in a General Population Study: Prevalence and Clinical Characteristics

Lina Ronnebjerg et al.

Summary: The study found a higher prevalence of severe asthma, with patients typically exhibiting more symptoms, activity limitations, heart disease, and lower lung function. Despite these impairments, many individuals with severe asthma did not have regular contact with healthcare providers.

JOURNAL OF ASTHMA AND ALLERGY (2021)

Add to Collection

Article Allergy

Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months

Moritz Z. Kayser et al.

Summary: Both mepolizumab and benralizumab are highly effective in the long-term treatment of severe eosinophilic asthma, showing significant improvements in pulmonary function, asthma control test scores, and reduction in oral corticosteroid use. There were no clinically relevant differences in outcomes after 12 months of therapy, and improvements were similar between the two groups after 6 and 12 months of treatment, indicating the feasibility of early treatment evaluation.

JOURNAL OF ASTHMA AND ALLERGY (2021)

Add to Collection

Article Allergy

A Real-World Evaluation of Clinical Outcomes of Biologicals and Bronchial Thermoplasty for Severe Refractory Asthma (BIOTERM)

Francesco Menzella et al.

Summary: This study compared different treatment options for patients with severe refractory asthma, including biologics and bronchial thermoplasty, and found that these treatments can significantly reduce hospitalizations, exacerbations, and oral corticosteroid use.

JOURNAL OF ASTHMA AND ALLERGY (2021)

Add to Collection

Article Allergy

Long-Term Therapy Response to Anti-IL-5 Biologics in Severe Asthma-A Real-Life Evaluation

Katrien Eger et al.

Summary: The study found that after 2 years of anti-IL-5 treatment, a favorable response was observed in the majority of severe asthma patients, including partial and super responders. Most partial responders showed impaired lung function or uncontrolled sinonasal disease.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

Add to Collection

Letter Allergy

The relationship between FENO and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma

Andrew P. Hearn et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

Add to Collection

Article Multidisciplinary Sciences

Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma

Giovanna Elisiana Carpagnano et al.

Summary: The study evaluated the clinical and economic impact of switching from omalizumab to mepolizumab in severe asthma patients. Results showed that switching to mepolizumab improved all clinical outcomes, reduced exacerbation rates, decreased steroid-dependent patients, and reduced lost working days. The incremental cost due to drug therapy was offset by savings in other cost items.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Allergy

Real-world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomes

Wei Chern Gavin Fong et al.

Summary: Through a retrospective analysis of clinical data, the application and efficacy of omalizumab and mepolizumab in different patient populations were investigated. Clinical studies showed that these two biologic drugs have significant effects on multiple clinical endpoints and patient baseline characteristics.

CLINICAL AND EXPERIMENTAL ALLERGY (2021)

Add to Collection

Review Allergy

Feasibility of Discontinuing Biologics in Severe Asthma: An Algorithmic Approach

Kazuki Hamada et al.

Summary: Biologics targeting key mediators of T2 inflammation have significantly improved management of severe asthma. Discontinuation of biologics may be feasible in subset of patients meeting specific criteria, such as absence of symptoms, controlled T2 inflammation, and other factors. Our proposed algorithm aims to guide physicians in decision-making for discontinuation of biologics.

JOURNAL OF ASTHMA AND ALLERGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Mepolizumab effectiveness in patients with severe eosinophilic asthma and co-presence of bronchiectasis: A real-world retrospective pilot

Claudia Crimi et al.

Summary: The study demonstrated that mepolizumab effectively improves asthma symptom control, reduces annual exacerbations, and corticosteroid intake in both severe eosinophilic asthma patients with and without bronchiectasis.

RESPIRATORY MEDICINE (2021)

Add to Collection

Article Allergy

Defining a Severe Asthma Super-Responder: Findings from a Delphi Process

John W. Upham et al.

Summary: Using a modified Delphi process, severe asthma experts developed an international consensus-based definition of a severe asthma super-responder, with major and minor criteria established. This definition is crucial for better understanding the prevalence, predictive factors, and mechanisms involved in super-responders, emphasizing the need for further research in these areas.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

Add to Collection

Article Critical Care Medicine

Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma

Joanne E. Kavanagh et al.

Summary: In patients with severe eosinophilic asthma treated with benralizumab, a significant reduction in asthma exacerbation rates was observed, with a subset of patients achieving super response. Blood eosinophil count increase was associated with treatment nonresponse.

CHEST (2021)

Add to Collection

Article Allergy

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma

Ioana Agache et al.

ALLERGY (2020)

Add to Collection

Article Respiratory System

Mepolizumab effectiveness and identification of super-responders in severe asthma

Erin S. Harvey et al.

EUROPEAN RESPIRATORY JOURNAL (2020)

Add to Collection

Review Allergy

An expert consensus framework for asthma remission as a treatment goal

Andrew Menzies-Gow et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)

Add to Collection

Article Critical Care Medicine

Real-World Effectiveness and the Characteristics of a Super-Responder to Mepolizumab in Severe Eosinophilic Asthma

Joanne E. Kavanagh et al.

CHEST (2020)

Add to Collection

Article Allergy

Real-word experience with mepolizumab: Does it deliver what it has promised?

Florence Schleich et al.

CLINICAL AND EXPERIMENTAL ALLERGY (2020)

Add to Collection

Review Allergy

Allergic Endotypes and Phenotypes of Asthma

Nicole Akar-Ghibril et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2020)

Add to Collection

Article Oncology

Effectiveness and safety of benralizumab for severe asthma in clinical practice (J-BEST): a prospective study

Takehiro Izumo et al.

ANNALS OF TRANSLATIONAL MEDICINE (2020)

Add to Collection

Article Allergy

A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting

Paolo Cameli et al.

INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY (2020)

Add to Collection

Review Allergy

Benralizumab: A New Approach for the Treatment of Severe Eosinophilic Asthma

Davila Gonzalez I et al.

JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY (2019)

Add to Collection

Review Critical Care Medicine

Inhaled Corticosteroid Therapy in Adult Asthma Time for a New Therapeutic Dose Terminology

Richard Beasley et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)

Add to Collection

Article Respiratory System

Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response

Marco Caminati et al.

EXPERT REVIEW OF RESPIRATORY MEDICINE (2019)

Add to Collection

Article Respiratory System

Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial

Andrew Menzies-Gow et al.

ERJ OPEN RESEARCH (2019)

Add to Collection

Review Allergy

Immunological and hematological effects of IL-5(Rα)-targeted therapy: An overview

M. Hassani et al.

ALLERGY (2018)

Add to Collection

Review Critical Care Medicine

Diagnosis and Management of Severe Asthma

Kian Fan Chung

SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2018)

Add to Collection

Article Cardiac & Cardiovascular Systems

Clinical and economic burden of severe asthma: A French cohort study

Clementine Nordon et al.

RESPIRATORY MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial

Peter G. Gibson et al.

LANCET (2017)

Add to Collection

Article Medicine, General & Internal

Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma

Parameswaran Nair et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Critical Care Medicine

Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial

Geoffrey L. Chupp et al.

LANCET RESPIRATORY MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

Eugene R. Bleecker et al.

LANCET (2016)

Add to Collection

Article Medicine, General & Internal

Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

J. Mark FitzGerald et al.

LANCET (2016)

Add to Collection

Article Immunology

Type 2 inflammation in asthma - present in most, absent in many

John V. Fahy

NATURE REVIEWS IMMUNOLOGY (2015)

Add to Collection

Article Respiratory System

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

Kian Fan Chung et al.

EUROPEAN RESPIRATORY JOURNAL (2014)

Add to Collection

Article Medicine, General & Internal

Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

Elisabeth H. Bel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Article Medicine, General & Internal

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

Hector G. Ortega et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Article Allergy

High Blood Eosinophil Count Is a Risk Factor for Future Asthma Exacerbations in Adult Persistent Asthma

Robert S. Zeiger et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2014)

Add to Collection

Article Critical Care Medicine

T-helper Type 2-driven Inflammation Defines Major Subphenotypes of Asthma

Prescott G. Woodruff et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2009)

Add to Collection

Article Critical Care Medicine

The global burden of asthma

Sidney S. Braman

CHEST (2006)

Add to Collection

Long-Term Real-World Outcomes of Mepolizumab and Benralizumab Among Biologic-Naive Patients With Severe Eosinophilic Asthma: Experience of 3 Years' Therapy

Related references

Export Citation

Share Paper